Stock Events

Stock Events

Context Therapeutics 

$2.51
29
-$0.14-5.28% Wednesday 06:41

Statistics

Day High
2.51
Day Low
2.51
52W High
-
52W Low
-
Volume
5
Avg. Volume
-
Mkt Cap
230.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-0.14
-0.12
-0.11
-0.09
Expected EPS
-0.1125
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-53.45MNet Income

Analyst Ratings

$7.00Average Price Target
The highest estimate is 9.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CNTX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Puma Biotechnology
PBYI
Mkt Cap256.89M
Puma Biotechnology focuses on the development and commercialization of drugs for the treatment of various forms of cancer, directly competing with Context Therapeutics' oncology focus.
Macrogenics
MGNX
Mkt Cap104.92M
MacroGenics is a company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, closely aligning with Context Therapeutics' mission.
TG Therapeutics
TGTX
Mkt Cap5.52B
TG Therapeutics focuses on the development of novel treatments for B-cell malignancies and autoimmune diseases, competing in the broader oncology and therapeutic market.
Kura Oncology
KURA
Mkt Cap891.41M
Kura Oncology is engaged in the research and development of medications aimed at the treatment of cancer, directly competing in the oncology space.
Array Technologies
ARRY
Mkt Cap1.32B
Array BioPharma, acquired by Pfizer, focuses on the discovery, development, and commercialization of targeted small molecule drugs to treat cancer, making it a competitor in the oncology drug market.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation specializes in the discovery, development, and commercialization of proprietary therapeutics, with a strong focus on oncology, competing in the same therapeutic area as Context Therapeutics.

About

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Show more...
CEO
ISIN
US21077P1084

Listings

F
DE
6K9.F
XNAS
US
CNTX
BOATS
BOATS
CNTX.BOATS

0 Comments

Share your thoughts

FAQ

What is Context Therapeutics stock price today?▼
The current price of CNTX.BOATS is $2.51 USD — it has decreased by -5.28% in the past 24 hours. Watch Context Therapeutics stock price performance more closely on the chart.
What is Context Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Context Therapeutics stocks are traded under the ticker CNTX.BOATS.
What is Context Therapeutics market cap?▼
Today Context Therapeutics has the market capitalization of 230.62M
When is the next Context Therapeutics earnings date?▼
Context Therapeutics is going to release the next earnings report on May 13, 2026.
What were Context Therapeutics earnings last quarter?▼
CNTX.BOATS earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.1 USD resulting in a -33.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Context Therapeutics revenue for the last year?▼
Context Therapeutics revenue for the last year amounts to 0 USD.
What is Context Therapeutics net income for the last year?▼
CNTX.BOATS net income for the last year is -53.45M USD.
When did Context Therapeutics complete a stock split?▼
Context Therapeutics has not had any recent stock splits.